Weekly Top News – Psoriasis – June 10, 2019

June 10, 2019

pegcantratinib (SNA-120) / Bio3 Research, Sienna
SNA-120, A Novel Topical Non-steroidal Therapy for Psoriasis and Associated Pruritus that Targets the NGF/TrkA Pathway: Results from a Multicenter Phase 2b Study (WCD 2019) – Jun 9, 2019 – Pres time: Jun 15, 2019; 10:35 AM – 10:45 AM; Location: YELLOW 3; No abstract available.

 

Taltz (ixekizumab) / Eli Lilly
Lilly to present new data and commitment to patient-centered solutions at the Annual European Congress of Rheumatology (Eli Lilly Press Release) – Jun 6, 2019 – “Eli Lilly…will present data for Taltz® (ixekizumab) and Olumiant® (baricitinib) at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid from June 12-15, 2019….The data include clinical studies of Taltz in the treatment of patients with psoriatic arthritis…Lilly will share in a late-breaking oral presentation the detailed results from the SPIRIT-H2H study…”

 

mirikizumab (LY3074828) / Eli Lilly; Taltz (ixekizumab) / Eli Lilly
Lilly to showcase scientific innovation within dermatology portfolio at 24th World Congress of Dermatology (Eli Lilly Press Release) – Jun 5, 2019 – “Eli Lilly and Company…will present data for Taltz (ixekizumab)…mirikizumab at the 24th World Congress of Dermatology (WCD) taking place June 10-15, 2019 in Milan, Italy….The data include 11 abstracts reflecting clinical studies of Taltz…Lilly will share short- and long-term health outcomes data, as well as long-term data on efficacy in patients with scalp psoriasis, from the Phase 2 clinical program of its investigational medicine mirkizumab for the treatment of moderate-to-severe plaque psoriasis.”

 

Tremfya (guselkumab) / J&J
Tremfya pricing: Average retail price of $11,800/1ml in US and €12,000/1ml in Portugal (Infinata) – Jun 7, 2019 – A subscription to Thomson ONE is required to gain full access to report 67022679; Page no: 14; REPORT TITLE: “AbbVie Inc. – Company Report”; AUTHORInfinata, et al; DATE: 06/03/2019

 

piclidenoson (CF101) / Can-Fite, China Medical System
Can-Fite participating in one-on-one partnering meetings at the BIO International Convention on June 3-6, 2019 (Can-Fite Biopharma Press Release) – Jun 4, 2019 – “Can-Fite BioPharma…announced today that the Company’s VP of Business Development, Sari Fishman, is conducting one-on-one meetings with pharmaceutical companies for potential distribution and partnerships for the Company’s drug candidates, Piclidenoson and Namodenoson, at the BIO International Convention 2019 on June 3-6, 2019 in Philadelphia….The Company currently has out-licensing agreements in several territories and has received approximately $17 million in upfront and milestone payments to date.”

 

Otezla (apremilast) / Celgene
Otezla sales projection: Tracking at $507M (US: $411M, ex-US: $96M) in Q2 2019 (RBC Capital Markets (Canada)) – Jun 4, 2019 – A subscription to Thomson ONE is required to gain full access to report 67384271; Page no: 3; REPORT TITLE: “Biotech: Noteworthy wkly Rx trends/forecast (HIV, HCV, MS, CGRP, TKI, Otezla): RBC biotech coverage w/e 5/17 – Wk 7 of 2Q”; AUTHOR: Abrahams, Brian, et al; DATE: 05/24/2019

 

Cosentyx (secukinumab) / Novartis
Cosentyx sales projection: $6B in 2022 (Jefferies) – Jun 5, 2019 – A subscription to Thomson ONE is required to gain full access to report 67382641; Page no: 1; REPORT TITLE: “Novartis AG – Our key takeaways from upbeat meet the management event”; AUTHOR: Welford, Peter, et al; DATE: 05/24/2019

 

Otezla (apremilast) / Celgene
Otezla sales projection: $1.9B in 2019 (Zacks) – Jun 5, 2019 – A subscription to Thomson ONE is required to gain full access to report 67403127; Page no: 6; REPORT TITLE: “Celgene Corporation(CELG) Zacks company report”; AUTHOR: Research Department; DATE: 05/28/2019

No Comments

Post a Comment

Comment
Name
Email
Website